Chlamydia Infection Diagnostics Market Revenue Expected to Reach $2.39 Billion by 2030 with 11.3% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Chlamydia Infection Diagnostics Market From 2026 To 2030?
The chlamydia infection diagnostics market size has experienced significant expansion in recent years. It is projected to increase from $1.4 billion in 2025 to $1.56 billion in 2026, growing at a compound annual growth rate (CAGR) of 11.5%. This growth in the past can be attributed to the enlargement of laboratory infrastructure, a rising incidence of chlamydia infections, the increased utilization of molecular diagnostics, an uplift in clinical testing volumes, and the availability of standardized diagnostic protocols.
The chlamydia infection diagnostics market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $2.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.3%. Key drivers for this growth during the forecast period include the escalating demand for quick and automated diagnostic methods, increased funding in laboratory automation, the proliferation of decentralized diagnostic testing, a heightened emphasis on detecting infections early, and ongoing advancements in molecular testing technologies. Prominent trends expected over the forecast timeframe encompass the wider implementation of sophisticated molecular diagnostic platforms, an increase in the uptake of PCR and LAMP-based tests, the greater incorporation of automation within diagnostic laboratories, an expansion of capabilities for high-throughput screening, and an intensified focus on the precision and speed of diagnostics.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18296&type=smp
What Key Drivers Are Influencing The Growth Of The Chlamydia Infection Diagnostics Market?
The increasing emphasis on preventive healthcare is anticipated to advance the chlamydia infection diagnostics market in the future. Preventive healthcare encompasses measures designed to prevent diseases rather than treat them after their onset, achieved through regular check-ups, vaccinations, and lifestyle adjustments. This rising focus on preventive healthcare seeks to reduce healthcare costs, improve the quality of life, and prevent the development of chronic diseases through early detection and proactive health interventions. In the context of chlamydia diagnostics, preventive healthcare is crucial, highlighting early detection, education, and routine screening to collectively diminish the spread and complications of chlamydia infections. For instance, in May 2023, data from the National Health Service (NHS), a UK-based publicly funded healthcare system, revealed that approximately 23.02 million diagnostic tests were carried out in March 2023, representing an increase of 223,100 tests compared to March 2022. Furthermore, in March 2023, the count of patients waiting for an essential diagnostic test reached 16.28 million, marking an increase of 59,400 relative to March 2022. Therefore, the heightened attention on preventive healthcare stimulates the expansion of the chlamydia infection diagnostics market.
Which Segments Are Included In The Analysis Of The Chlamydia Infection Diagnostics Market?
The chlamydia infection diagnostics market covered in this report is segmented –
1) By Test Type: Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test, Other Test Types
2) By Type Of Infections: Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection
3) By Application: Hospitals, Specialty Clinics, Diagnostic Centers
4) By End User: Diagnostics, Therapeutics
Subsegments:
1) By Culture Test: Cell Culture, Egg Culture
2) By Nucleic Acid Amplification Test (NAAT): PCR-Based Test, LAMP-Based Test
3) By Direct Fluorescent Antibody Test: Direct Fluorescent Antibody Staining, Direct Fluorescent In-Situ Hybridization
4) By Serology Test: Immunoassays, Enzyme Immunoassay (EIA)
5) By Other Test Types: Enzyme-Linked Immunosorbent Assay (ELISA), Hybrid Capture Test
What Key Developments And Trends Are Impacting The Chlamydia Infection Diagnostics Market?
Companies active in the chlamydia infection diagnostic market are concentrating on creating advanced products, including molecular point-of-care testing platforms, to achieve a competitive advantage. Molecular point-of-care (POC) testing platforms are diagnostic instruments crafted to identify and examine specific nucleic acids (DNA or RNA) from pathogens directly where the patient is being cared for. For example, in May 2024, Sherlock Biosciences, a US-based biotech company, disclosed the creation of the Sherlock test, recognized as one of the first molecular disposable tests for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG). The results from this diagnostic test are delivered in under 30-minutes, following the analysis of DNA and RNA gathered through self-collected penile meatal or vaginal swabs.
Which Key Industry Participants Are Active In The Chlamydia Infection Diagnostics Market?
Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics
Read the full chlamydia infection diagnostics market report here:
Which Region Is Expected To Register The Fastest Growth In The Chlamydia Infection Diagnostics Market?
North America was the largest region in the chlamydia infection diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Chlamydia Infection Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18296&type=smp
Browse Through More Reports Similar to the Global Chlamydia Infection Diagnostics Market 2026, By The Business Research Company
Chlamydia Infection Diagnostics Global Market Report
Chlamydia Infection Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report
Chlamydia Trachomatis Ct And Neisseria Gonorrhoeae Ng Testing Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
